A new study shows that bortezomib, a drug used for Multiple Myeloma, may help overcome resistance to immunotherapy in Non-Small Cell Lung Cancer. Researchers found the drug prevents the breakdown of the interferon-gamma receptor (IFNGR1), a key molecule tumors often destroy to avoid immune detection. By preserving this receptor, cancer cells become more visible and responsive to immune attack.
Bortezomib also activates the STING pathway by causing stress and DNA damage in tumor cells. This triggers immune signals that recruit more CD8+ T cells into tumors, strengthening the body’s anti-cancer response. When combined with anti–PD-L1 therapy, the approach produced stronger immune activity and better tumor control than standard chemotherapy combinations in preclinical models.
The study also found that immunotherapy improves blood vessel function in tumors, helping bortezomib penetrate more effectively. This overcomes a major limitation seen in past studies of solid tumors. Overall, the findings suggest bortezomib could enhance immunotherapy and support future clinical trials in lung cancer.